+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Urokinase-type plasminogen activator enhances endothelial cell differentiation through a non-proteolytic mechanism involving uPA receptor binding



Urokinase-type plasminogen activator enhances endothelial cell differentiation through a non-proteolytic mechanism involving uPA receptor binding



Pediatric Research 35(4 Part 2): 373A




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 034144253

Download citation: RISBibTeXText


Related references

Urokinase-type plasminogen activator/type-2 plasminogen-activator inhibitor complexes are not internalized upon binding to the urokinase-type-plasminogen-activator receptor in THP-1 cells: Interaction of urokinase-type plasminogen activator/type-2 plasminogen-activator inhibitor complexes with the cell surface. European Journal of Biochemistry 233(2): 514-519, 1995

Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis. Journal of Urology 174(2): 461-465, 2005

Differential effects of acute and chronic wound fluids on urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor, and tissue-type plasminogen activator in cultured human keratinocytes and fibroblasts. Wound Repair & Regeneration 9(4): 314-322, July-August, 2001

Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors. Oncology Reports 26(6): 1555-1560, 2012

Aggregated low-density lipoprotein induce impairment of the cytoskeleton dynamics through urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor in human vascular smooth muscle cell. Journal of Thrombosis and Haemostasis 10(10): 2158-2167, 2013

Nipple aspirate fluid expression of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor predicts breast cancer diagnosis and advanced disease. Annals of Surgical Oncology 10(8): 948-953, 2003

Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients. Breast Cancer Research & Treatment. 49(1): 41-50,, 1998

Urokinase-type plasminogen activator , urokinase-type plasminogen activator receptor , plasminogen activator inhibitor type 1 , type 2 , and tissue-type plasminogen activator in breast cancer cells. Fibrinolysis & Proteolysis 14(Suppl. 1): 38, 2000

Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system. Cancer Research 66(8): 4173-4181, 2006

Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cells. Oncology Reports 17(5): 1259-1268, 2007

Characterization of messenger rna for the endothelial cell urokinase type plasminogen activator receptor. Circulation 82(4 Suppl. 3): III373, 1990

Identification of a human endothelial cell urokinase type plasminogen activator receptor. Arteriosclerosis 8(5): 702A, 1988

Characterization of the binding of urokinase-type plasminogen activator (u-PA) to plasminogen, to plasminogen-activator inhibitor-1 and to the u-PA receptor. European Journal of Biochemistry 224(2): 567-574, 1994

Urokinase-type plasminogen activator mediates basic fibroblast growth factor-induced bovine endothelial cell migration independent of its proteolytic activity. Journal of Cellular Physiology 150(2): 258-263, 1992

Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and alpha(2)-macroglobulin receptor in human breast carcinomas. International Journal of Cancer 66(4): 441-452, 1996